Medical devices maker OrthoPediatrics' Q3 adjusted EBITDA misses estimates

Orthopediatrics

28/10/2025 20:13

Overview

OrthoPediatrics Q3 revenue grows 12% yr/yr to $61.2 mln, driven by Trauma & Deformity

Adjusted EBITDA for Q3 rises 56% yr/yr but misses analyst expectations

Company reports GAAP diluted loss per share of $0.50, non-GAAP loss of $0.24

Outlook

Company forecasts full-year 2025 revenue between $233.5 mln and $234.5 mln

Company aims for free cash flow break-even in 2026

Result Drivers

TRAUMA & DEFORMITY GROWTH - Co attributes 17% revenue growth in Trauma & Deformity to strong performance of PNP Femur, PNP Tibia, DF2, and OPSB products

SCOLIOSIS SALES - Scoliosis revenue increased 4%, driven by Response and ApiFix non-fusion system sales, offset by decline in 7D unit sales

DOMESTIC REVENUE INCREASE - Domestic revenue rose 14%, driven by strong sales in core product lines, despite challenges in 7D sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.50
Q3 Net Income
-$11.80 mln
Q3 Adjusted EBITDA
Miss
$6.20 mln
$6.49 mln (6 Analysts)
Q3 Gross Margin
74%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for OrthoPediatrics Corp is $23.00, about 26.3% above its October 27 closing price of $16.96

Press Release: ID:nGNX5B27rz

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)